Benzinga | Apr 5, 2021 09:29AM EDT

Invitae Accelerates Personalized Oncology Testing With Genosity Acquisition

* Invitae Corp (NYSE: NVTA) has agreed to acquire Genosity Inc, a genomics company offering software and laboratory solutions to enable the development and deployment of complex sequencing-based tests.

* Deal consideration of approximately $200 million includes roughly $120 million in cash and roughly $80 million in Invitae common stock.

* Invitae is currently developing its Personalized Cancer Monitoring (PCM) platform as an in vitro diagnostic.

* The acquisition would bring Genosity's specialized capabilities onto the Invitae platform to accelerate its personalized oncology offerings.

* PCM analyzes a patient's genetic profile of their specific cancer and uses it to monitor their blood to detect cancer recurrence early when it is most curable.

* Invitae's PCM test, if approved for use, will be augmented by Genosity technology and capabilities to distribute PCM globally.

* In connection with the transaction, Invitae will grant restricted stock units of up to $15 million to certain continuing employees of Genosity.

* Additionally, SoftBank Group Corp (OTC:SFTBY) plans to lead an investment of nearly $1.15 billion into Invitae in the form of convertible debt.

* The notes have an initial conversion price of $43.18 per share.

* Price Action: NVTA shares are up 9.5% at $42.9 on the last check Monday.